<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04151719</url>
  </required_header>
  <id_info>
    <org_study_id>SAL-REL-2043</org_study_id>
    <nct_id>NCT04151719</nct_id>
  </id_info>
  <brief_title>An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer</brief_title>
  <official_title>An Open-Label Extension Study to Evaluate the Safety and Efficacy of Oral Methylnaltrexone Bromide Tablets in Subjects With Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label extension study will evaluate the long-term safety and efficacy of oral MNTX
      in participants with advanced pancreatic cancer (adenocarcinoma) who were previously enrolled
      in Study SAL-REL-2042 (NCT04083651).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 3, 2020</start_date>
  <completion_date type="Anticipated">February 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 3, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From first MNTX dose administration until death from any cause (up to 4 years)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>MNTX 450 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive methylnaltrexone bromide (MNTX) 450 milligrams (mg) (3 tablets of 150 mg each) once daily (QD) orally. Treatment will continue until participant's death or early withdrawal from the study or study termination by the sponsor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylnaltrexone bromide (MNTX)</intervention_name>
    <description>Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.</description>
    <arm_group_label>MNTX 450 mg QD</arm_group_label>
    <other_name>Relistor®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult participants greater than or equal to (≥)18 years of age on the date the
             Informed Consent Form (ICF) is signed, with the capacity to provide voluntary informed
             consent.

          -  Enrolled in double-blind Study SAL-REL-2042 (NCT04083651) and completed an end of
             study (EOS) visit (Day 168) or completed Day 56 of the Study SAL-REL-2042
             (NCT04083651).

          -  Must be able to read, understand, and provide written informed consent on the
             Institutional Review Board (IRB)-approved ICF and provide authorization, as
             appropriate, for local privacy regulations.

          -  Willing and able to comply with scheduled visits, the treatment plan, and laboratory
             tests.

          -  Signed an informed consent/Health Insurance Portability and Accountability Act (HIPAA)
             form.

        Exclusion Criteria:

          -  Concurrent therapy with any other investigational agent during the study.

          -  Current use of a peripherally acting mu-opioid-receptor antagonist.

          -  Current evidence of untreated brain metastasis(es).

          -  Diarrhea greater than Grade 1, based on the National Cancer Institute Common
             Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0).

          -  Bowel obstruction.

          -  Advanced liver disease.

          -  Renal disease.

          -  Any other severe, acute, or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, or may interfere with the interpretation of study results, and in
             the judgment of the Principal Investigator, would make the participant inappropriate
             for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Lahey</last_name>
    <role>Study Director</role>
    <affiliation>Bausch Health Americas, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Manager</last_name>
    <phone>908-541-8615</phone>
    <email>Stephen.Rodgers@bauschhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Harris</last_name>
    <email>Susan.Harris@bauschhealth.com</email>
  </overall_contact_backup>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Methylnaltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

